Open AccessPharmacokinetics and Pharmacodynamics of Clofazimine for Treatment of Cryptosporidiosis
Author(s) -
Cindy X. Zhang,
Melissa S. Love,
Case W. McNamara,
Victor Chi,
Ashley Woods,
Sean B. Joseph,
Deborah A. Schaefer,
Dana P. Betzer,
Michael W. Riggs,
Pui-Ying Iroh Tam,
Wesley C. Van Voorhis,
Samuel Arnold
Publication year - 2022
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01560-21
Subject(s) - clofazimine , cryptosporidium , medicine , nitazoxanide , pharmacodynamics , pharmacology , pharmacokinetics , adverse effect , dosing , immunology , leprosy , biology , microbiology and biotechnology , feces
Infection withCryptosporidium spp. can cause severe diarrhea, leading to long-term adverse impacts and even death in malnourished children and immunocompromised patients. The only FDA-approved drug for treating cryptosporidiosis, nitazoxanide, has limited efficacy in the populations impacted the most by the diarrheal disease, and safe, effective treatment options are urgently needed.